<DOC>
	<DOCNO>NCT00033644</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Colony-stimulating factor sargramostim may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . PURPOSE : Phase II trial study effectiveness combination chemotherapy plus sargramostim treating patient advance , persistent , recurrent cancer uterus .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Sargramostim Treating Patients With Cancer Uterus</brief_title>
	<detailed_description>OBJECTIVES : - Determine antitumor activity dacarbazine , mitomycin , doxorubicin , cisplatin plus sargramostim ( GM-CSF ) patient advance , persistent , recurrent leiomyosarcoma uterus . - Determine nature degree toxicity regimen patient . OUTLINE : Patients receive dacarbazine IV 2 hour , follow mitomycin IV 2-5 minute , doxorubicin IV 2-5 minute , cisplatin IV 2 hour day 1 . Patients also receive sargramostim ( GM-CSF ) subcutaneously ( SC ) every 12 hour day -6 -3 first chemotherapy course day 2-15 23-26 chemotherapy course . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients achieve stable disease receive maximum 4 course . Patients achieve complete partial response receive maximum 6 course . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 12-43 patient accrue study within 12-28 month .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Leiomyosarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary leiomyosarcoma ( LMS ) uterus Advanced , persistent , recurrent disease refractory curative therapy establish treatment At least 1 unidimensionally measurable target lesion At least 20 mm conventional technique ( e.g. , palpation , plain xray , CT scan , MRI ) OR At least 10 mm spiral CT scan Tumors within previously irradiate field designate nontarget lesion Ineligible high priority Gynecologic Oncology Group protocol ( one exist ) , include active phase III protocol population PATIENT CHARACTERISTICS : Age : 18 Performance status : GOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT great 2.5 time ULN Alkaline phosphatase great 2.5 time ULN Renal : Creatinine great 1.5 time ULN Other : No active infection require antibiotic No grade 2 great sensory motor neuropathy No invasive malignancy within past 5 year except nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior cytotoxic chemotherapy LMS uterus Endocrine therapy : At least 1 week since prior hormonal therapy LMS uterus Concurrent hormone replacement therapy allow Radiotherapy : See Disease Characteristics Recovered prior recent radiotherapy Surgery : Recovered prior recent surgery Other : Recovered prior recent therapy No prior cancer treatment would preclude study therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2004</verification_date>
	<keyword>stage IV uterine sarcoma</keyword>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>uterine leiomyosarcoma</keyword>
</DOC>